Compounds > 1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride
Page last updated: 2024-12-07
1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride
Description
You are referring to **1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride**, which is a synthetic compound with the following chemical formula: C24H27FN4O3 · HCl.
**This compound is a derivative of the piperazine class of molecules and exhibits several interesting pharmacological properties.** It has been investigated for its potential therapeutic use in the following areas:
* **Antidepressant Activity:** Some studies suggest that this compound might have antidepressant effects due to its ability to interact with serotonin receptors, which are implicated in mood regulation. However, further research is needed to confirm this activity.
* **Anti-inflammatory Activity:** The compound has demonstrated anti-inflammatory properties in certain experimental models. This could be related to its ability to modulate signaling pathways involved in inflammation.
* **Antioxidant Activity:** Preliminary research suggests that this compound might possess antioxidant properties, which could be beneficial in protecting cells from damage caused by free radicals.
**Importance for Research:**
This compound is of interest for research because it displays a unique combination of potential pharmacological activities. Its structure, with the fluorobenzoyl group and the 7-methoxy-1-naphthyl moiety, might contribute to its specific interactions with biological targets.
**Further Research:**
While promising, the research on this compound is still in its early stages. More studies are needed to:
* **Confirm its precise mechanism of action.**
* **Determine its safety and efficacy in animal models.**
* **Evaluate its potential for human clinical trials.**
It's crucial to note that this compound is **not currently approved for any therapeutic use** and should not be used without proper medical supervision.
1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride: a 5-HT(1A) receptor agonist; RN given for HCl salt [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
4-fluoro-N-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}benzamide hydrochloride : A hydrochloride salt that is obtained by reaction of 4-fluoro-N-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}benzamide with one equivalent of hydrogen chloride. Highly potent selective 5-HT1A receptor full agonist (pKi values are 9.0, 6.6, 7.5, 6.6 and < 6.0 for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2 and 5-HT3 receptors respectively). Possibly binds between the agonist binding site and the G protein interaction switch site, affecting the activation mechanism, and may display positive cooperativity. Anxiolytic following central administration in vivo. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
ID Source | ID |
PubMed CID | 131905 |
CHEBI ID | 64099 |
SCHEMBL ID | 3187184 |
MeSH ID | M0244955 |
Synonyms (33)
Synonym |
benzamide, 4-fluoro-n-(2-(4-(7-methoxy-1-naphthalenyl)-1-piperazinyl)ethyl)-, hydrochloride |
4-fluoro-n-(2-(4-(7-methoxy-1-naphthalenyl)-1-piperazinyl)ethyl)benzamide hydrochloride |
098102ri3w , |
s 24506 |
unii-098102ri3w |
4-fluoro-n-{2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl}benzamide hydrochloride |
135721-98-1 |
s 14506 hydrochloride |
1-((4-fluorobenzoylamino)ethyl)-4-(7-methoxy-1-naphthyl)piperazine hydrochloride |
FT-0643238 |
4-fluoro-n-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]benzamide hydrochloride |
s14506 hydrochloride |
s 14506 monohydrochloride |
CHEBI:64099 |
s14506 monohydrochloride |
AKOS022180966 |
SCHEMBL3187184 |
4-fluoro-n-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]benzamidehydrochloride |
DTXSID4042628 |
286369-38-8 |
s-14506 hydrochloride |
benzamide,4-fluoro-n-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-,hydrochloride (1:?) |
SR-01000597765-1 |
sr-01000597765 |
J-006763 |
4-fluoro-n-(2-(4-(7-methoxynaphthalen-1-yl)piperazin-1-yl)ethyl)benzamide hydrochloride |
Q27133029 |
MS-28000 |
4-fluoro-n-[2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl]benzamide;hydrochloride |
HY-110024 |
s-14506 (hydrochloride) |
benzamide,4-fluoro-n-[2-[4-(7-methoxy-1-naphthalenyl)-1-piperazinyl]ethyl]-,hydrochloride(1:?) |
s14506hydrochloride |
Research Excerpts
Bioavailability
Dosage Studied
Roles (2)
Role | Description |
serotonergic agonist | An agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders. |
anxiolytic drug | Anxiolytic drugs are agents that alleviate anxiety, tension, and anxiety disorders, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
Class | Description |
hydrochloride | A salt formally resulting from the reaction of hydrochloric acid with an organic base. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (60.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.00
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.00 (24.57) | Research Supply Index | 2.20 (2.92) | Research Growth Index | 4.20 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |